GlassScriptPhysician profile
Cedric W Spak
NPI 1063575199
$426,973.65
in general payments reported to CMS, 2019-2025
31 companies · $86K in 2025
The $86K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $47K · 2021: $23K · 2022: $14K · 2023: $142K · 2024: $44K · 2025: $86K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Travel and Lodging: $41K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $35K · Consulting Fee: $23K · Food and Beverage: $7,644 · Education: $1.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166,670.00 |
| Travel and Lodging | $40,619.66 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $34,835.00 |
| Consulting Fee | $22,821.50 |
| Food and Beverage | $7,644.33 |
| Education | $1.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $163,001.65 | 2022-2025 | Livtencity |
| Shionogi INC | $44,604.61 | 2020-2025 | Fetroja |
| Genentech USA, INC. | $43,343.10 | 2019-2021 | |
| Astellas Pharma US INC | $35,619.63 | 2019-2024 | Cresemba |
| Abbvie INC. | $27,463.52 | 2021-2025 | Avycaz, Dalvance |
| Allergan, INC. | $26,814.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $21,700.84 | 2019-2023 | Recarbrio, Zerbaxa, Dificid |
| Insmed, INC. | $21,408.64 | 2019-2025 | Arikayce, Brinsupri |
| Invivyd INC | $13,341.69 | 2024-2025 | Pemgarda |
| La Jolla Pharmaceutical Company | $8,382.16 | 2021-2025 | Zevtera, Xacduro, Xerava |
| Melinta Therapeutics, LLC | $7,490.45 | 2019-2024 | Kimyrsa, Rezzayo, Vabomere |
| Biofire Diagnostics, LLC | $6,000.00 | 2020 | |
| Theratechnologies INC. | $2,537.40 | 2019-2022 | |
| Pfizer INC. | $1,823.99 | 2025 | |
| Cipla USA INC. | $1,095.43 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $417.29 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Viiv Healthcare Company | $414.91 | 2019-2025 | Dovato, Cabenuva |
| Kamada LTD. | $313.27 | 2023-2024 | |
| Gilead Sciences, INC. | $205.91 | 2020-2025 | |
| Cumberland Pharmaceuticals, INC. | $191.76 | 2019-2023 | Vibativ |
| Janssen Biotech, INC. | $178.54 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $154.29 | 2019-2024 | Nuzyra |
| Ferring Pharmaceuticals INC. | $147.17 | 2025 | Rebyota |
| Access Pro Medical, LLC | $113.29 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $55.72 | 2019 | |
| Eurofins Viracor, LLC | $45.93 | 2024 | |
| Octapharma USA, INC. | $30.25 | 2023 | Panzyga |
| Aimmune Therapeutics, INC. | $29.90 | 2025 | Vowst |
| Janssen Products, LP | $19.98 | 2019 | |
| Dynavax Technologies Corporation | $14.23 | 2019 | |
| Nabriva Therapeutics, Plc | $13.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cedric Spak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.